Related Experiment Video
Updated: Oct 13, 2026

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
Aortic-renal aneurysm in a patient with VEXAS syndrome treated with Tocilizumab
Senol Kobak1, Mehmet Hilmi Dogu1, Ali Baran Budak2
1Istinye University Faculty of Medicine.
Abstract:
VEXAS syndrome is adult onset autoinflammatory disease caused by somatic mutations in the gene UBA1 and characterized with overlapping rheumatologic and hematologic clinical features. The most common clinical features included recurrent fever, artralgia/arthritis, pulmonary involvement, skin lessions, vasculitis, and/or thromboembolic event. Aortic-renal aneurysm in VEXAS syndrome is rare entity and its associated with poor prognosis. Herein we described a 69 year-old male patient with VEXAS syndrome with aortic-renal aneurysm responded well to Tocilizumab treatment.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Vascular Spasm
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Aneurysm III: Interprofessional Care
Rheumatic Heart Disease III: Medical Management
